Back to companies

Biophytis SA: Overview

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Select Item

Biophytis SA (Biophytis) is a biotechnology company. It focuses on developing therapeutics aimed at slowing degenerative processes associated with aging and improving functional outcomes for patients with age related diseases. It focuses on therapeutic solutions against age-related, impairing diseases. The company's product pipeline includes Sarconeos (BIO101), a first-in-class drug candidate for the treatment of sarcopenic obesity. The company develops drug candidates based on SARCOB and MACULIA technological platforms. Biophytis is headquartered in Paris, Ile-de-France, France.

 Gain a 360-degree view of Biophytis SA and make more informed decisions for your business Gain a 360-degree view of Biophytis SA and make more informed decisions for your business Register your interest
Headquarters France
Address 14 Avenue De L'Opera, Paris, Ile-de-France, 75001
Website www.biophytis.com
Telephone 33 1 41836600
No of Employees 18
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange ALBPS (EPA)
EPS XYZ
Net Income (2024) XYZ 39% (2024 vs 2023)
Market Cap* $4.9M
   
   
* As of and is in US$
View Biophytis SA financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Register your interest

Biophytis SA premium industry data and analytics

50+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Biophytis SA’s relevant decision makers and contact details.

30+

Catalyst Calendar

Proactively evaluate Biophytis SA’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

18+

Clinical Trials

Determine Biophytis SA go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

4

Pipeline Drugs

Identify which of Biophytis SA’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

3

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

1

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

Products and Services

Products
Pipeline
Sarconeos (BIO 101):
Sarcopenia and Duchenne Muscular Dystrophy (DMD)
XYZ
XYZ
XYZ
Understand Biophytis SA portfolio and identify potential areas for collaboration Understand Biophytis SA portfolio and identify potential areas for collaboration Register your interest
Image for loader

Competitor Comparison

Key Parameters Biophytis SA NicOx SA Anagenesis Biotechnologies SAS Crescent Biopharma Inc Quince Therapeutics Inc
Headquarters France France France United States of America United States of America
City Paris Biot Strasbourg Waltham San Francisco
State/Province Ile-de-France Provence - Alpes- Cote d'Azur Alsace Massachusetts California
No. of Employees 18 11 - 4 36
Entity Type Public Public Private Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Register your interest
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Register your interest
Executives
Name Position Board Since Age
Waly Dioh Ph.D Chief Operating Officer Senior Management - -
Edouard Bieth Chief Strategy Officer Senior Management - -
Rob van Maanen MD Chief Medical Officer Senior Management - -
Pierre J Dilda Chief Scientific Officer Senior Management - -
Chiara Baccelli Director Of Pharmaceutical Operations And Quality Assurance Senior Management - -
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Gain insight into Biophytis SA key executives to enhance your sales strategy Gain insight into Biophytis SA key executives to enhance your sales strategy Register your interest
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Why are you leaving?